You Position: Home > Paper
Do newer antihypertensives play better than older ones?——Lessons learned from the ASCOT-BPLA trial
( views:105, downloads:0 )
- Author:
- No author available
- Journal Title:
- CHINESE MEDICAL JOURNAL
- Issue:
- 21
- DOI:
- No doi available
- Key Word:
- No keyword available
Abstract： @@ Hypertension has currently become a centennial epidemic and key public health problem in China. According to an investigation among 15 540 adults from 2000 to 2001 by Gu and co-workers,1 the prevalence of hypertension among people aged 35 to 74 years has reached 27.2%, ranking among the highest rates of hypertension in the world and putting the blood pressure (BP) of nearly 130 million Chinese adults above the normal level.
- [1]Wedel H,Sever PS,Nieminen M,etc.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ran[J].2003,361(9364).
- [2]Wedel H,Nieminen M,Caulfield M,etc.Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).[J].2005,366(9489).
- [3]Duan X,He J,Reynolds K,etc.Major causes of death among men and women in China.[J].2005,353(11).